Society of Nuclear Medicine and Molecular Imaging Awards Dr. Calais the Gambhir Lecture Award

2026-11-19 09:10

Recently, the Society of Nuclear Medicine and Molecular Imaging (SNMMI) officially announced the selection of Dr. Jeremie·Calais, adjunct professor at the University of California, Los Angeles (UCLA) and internationally renowned leader in nuclear medicine and theranostics, to deliver the “Dr. Sanjiv·Sam·Gambhir Annual Lecture in Nuclear Medicine Treatments and Diagnostics” (Dr. Sanjiv "Sam" Gambhir Annual Lecture in Nuclear Medicine Treatments and Diagnostics), in recognition of his outstanding contributions to advancing cancer imaging and targeted therapy.

This prestigious lectureship honor aims to recognize industry leaders who advance early disease detection, precision medicine, and personalized therapy through cutting-edge research. After receiving the award, Dr. Jeremie·Calais, adjunct professor at the University of California, Los Angeles, stated that Dr. Gambhir's visionary insights into early disease detection and the development of more precise personalized therapies have had a profound impact on the field, and that receiving this recognition is a tremendous honor while also providing a valuable opportunity to review the development history of theranostics and look forward to its boundless future possibilities.

Dr. Jeremie·Calais has long been committed to advancing the clinical application of molecular imaging and targeted radiopharmaceutical therapies in cancer patients. His outstanding research achievements directly contributed to the U.S. Food and Drug Administration (FDA)'s first approval in 2020 of a Prostate-Specific Membrane Antigen (PSMA) positron emission tomography (PET) imaging agent, and successfully established radioligand therapy as a key treatment option for patients with advanced prostate cancer.

In addition, Dr. Calais served as the head of the UCLA theranostics clinical research program, co-chaired the establishment of a dedicated theranostics treatment center, and helped establish the first independent Department of Nuclear Medicine and Theranostics in the United States. With the implementation and promotion of these innovations, the diagnostic and therapeutic efficacy of nuclear medicine in the field of precision oncology has been further enhanced, bringing new hope to cancer patients worldwide.

Disclaimer: Information republished from partner media, institutions or other websites is provided for reference and communication purposes only. It does not imply endorsement of its views or verification of its accuracy. Please contact us if any content infringes rights or requires correction.